Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.79
-0.21 (-1.31%)
At close: Apr 7, 2026, 4:00 PM EDT
16.00
+0.21 (1.33%)
Pre-market: Apr 8, 2026, 7:00 AM EDT
Aurinia Pharmaceuticals Revenue
In the year 2025, Aurinia Pharmaceuticals had annual revenue of $283.06M with 20.38% growth. Aurinia Pharmaceuticals had revenue of $77.11M in the quarter ending December 31, 2025, with 28.81% growth.
Revenue (ttm)
$283.06M
Revenue Growth
+20.38%
P/S Ratio
7.42
Revenue / Employee
$2,211,367
Employees
128
Market Cap
2.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.06M | 47.92M | 20.38% |
| Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
| Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
| Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
| Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
| Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
| Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
| Dec 31, 2018 | 463.00K | 45.00K | 10.77% |
| Dec 31, 2017 | 418.00K | 245.00K | 141.62% |
| Dec 31, 2016 | 173.00K | -1.00M | -85.29% |
| Dec 31, 2005 | 1.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Adaptive Biotechnologies | 276.98M |
| Stoke Therapeutics | 184.42M |
| Syndax Pharmaceuticals | 172.35M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 55.23M |
| Agios Pharmaceuticals | 54.03M |
AUPH News
- 9 days ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 15 days ago - MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition - Business Wire
- 15 days ago - Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning - Benzinga
- 16 days ago - Aurinia Announces Management Transition - Business Wire
- 5 weeks ago - Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets - Benzinga
- 5 weeks ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - Business Wire
- 6 weeks ago - Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 - Business Wire
- 5 months ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress - Business Wire